{"id":"W2601946099","doi":"10.1200/jco.2014.32.15_suppl.tps5629","title":"Phase II study of XL184 (cabozantinib) in recurrent or metastatic endometrial cancer: A trial of the PMH, Chicago, and California Phase II Consortia.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Cancer Care Ontario; Juravinski Cancer Centre; University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cabozantinib; Oncology; Internal medicine; Clinical endpoint; Endometrial cancer; Progression-free survival; Cancer; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Chemotherapy; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001731568,0.001115595,0.0009026031,0.0003714644,0.000349764,0.000528244,0.0006358227,0.00105521,0.006603665],"category_scores_gemma":[0.0007233539,0.0004995512,0.000686211,0.0003610894,0.0005820603,0.0003759798,0.000292752,0.001561636,0.0008559431],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008154751,"about_ca_system_score_gemma":0.002303445,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002133483,"about_ca_topic_score_gemma":0.005695698,"domain_scores_codex":[0.9996487,0.0002121848,0.00001289247,0.00004804341,0.00003602006,0.00004223673],"domain_scores_gemma":[0.9994771,0.00007704386,0.00009429894,0.00002993593,0.00003457197,0.0002871205],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7703504,0.02702004,0.007900086,0.00114947,0.001007238,0.0003103709,0.0002705378,0.002138476,0.02702453,0.0007474492,0.01500501,0.1470765],"study_design_scores_gemma":[0.8368738,0.1490681,0.006982865,0.00003766183,0.0002354289,0.0001678475,0.00003162163,0.000676515,0.001026104,0.0001330599,0.004753659,0.00001335449],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9710596,0.006945953,0.001091889,0.001818757,0.000275003,0.009889615,0.002620694,0.0002522861,0.006046112],"genre_scores_gemma":[0.9609421,0.004756345,0.005216928,0.002154893,0.0003321514,0.01016486,0.004999697,0.00005695081,0.01137591],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006603665,"threshold_uncertainty_score":0.02209145,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2113546195443331,"score_gpt":0.511895850200911,"score_spread":0.3005412306565779,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}